Scott Brown
Kristin Bloink
Kristin Bloink manages all internal discovery efforts and all external technology evaluations and subsequent portfolio entries for R&D. She has 26 years of accomplishments in human clinical trials, animal drug discovery and development, translational model development and execution, and human and veterinary clinical medical delivery in the private as well as the military sector. She joined Novartis Animal Health in 2007 and integrated into Elanco Animal Health in 2015.
Brian Kopp
Brian Kopp is a Partner at Stonehaven Consulting AG. He has 20 years of experience in Healthcare with Eli Lilly and Company, and 7 years of experience in Automotive with General Motors. Since 2007, Brian has served as CFO and V.P. of Operations and Strategy with Elanco Animal Health, a division of Eli Lilly and Company. Over this period, Elanco has grown Revenues from $700 million to over $3 billion, emerged as a top tier player in the industry, achieved top tier Operating margins, experienced significant expansion of business lines, global capabilities, and overall value. This significant growth was achieved by executing on an aggressive transformation agenda that included capitalizing on a mix of organic and inorganic opportunities. After 27 years working in increasingly relevant roles within Corporate settings, Brian is excited by the opportunity to take his experiences and insights and help Animal Health partners develop and/or realize their strategic goals.
Richard Dennett
Tim Adetona, M.Sc., D.PH
Tim has a broad regulatory expertise of close to 20 years’ experience (5 as Consultant) in addressing and obtaining regulatory authorization for various life-science products including drugs, biologics and innovative nutritional products in Europe, as well as statutory regulatory requirements in global markets including the USA and emerging markets.
Tim has acquired significant knowledge of Swiss regulations and Swissmedic procedures and has successfully managed a number of MAA submissions for drugs and biologics. Tim has substantial experience in all steps of product development from preclinical to life-cycle management, including those involving specialized conditions as orphan drug designations, accelerated or fast-track assessment procedures and compassionate use programs.
Tim also has responsibility for the management of projects involving the design and implementation of global regulatory strategies for the development, evaluation and marketing of nutritional and innovative food-drug borderline products. Tim is equally well versed in regulatory engagements involved with the development of Personal, Health and Beauty Care products (cosmetics, deodorants and antiperspirants), as well as Medical Devices and OTC medicines.
Prior to joining VCLS, Tim was Regulatory Affairs Director, Consumer Health Care International (CHCI) for Vifor Pharma, where he provided directional leadership for the implementation of all aspects of Regulatory Affairs related to Consumer Health Care products in global markets and successfully expanded the experience he had gained as Senior Regulatory Affairs Manager for Procter & Gamble.
Kim Nguyen, PhD
Kim is a part of the Cell Therapy team at Precision Biosciences focused on the process development, analytics, and manufacturing of allogeneic CAR-T cell products. Before joining Precision Biosciences, she served as Principal Scientist and Senior Manager for Strategic Initiatives at Terumo BCT. Kim received her AB from Princeton University and her Ph.D. from Columbia University, both in Chemistry. She enjoys cooking Vietnamese food, reading, and adventures with her adorable Jack Russell terrier, Grover, aka Mr. Shambles.
Dr Zoltan Ivics
Ryan Aresnault
Dr. Ryan Arsenault is currently an Assistant Professor in the Department of Animal and Food Sciences at the University of Delaware. Dr. Arsenault’s research at UD centers on kinomics and gut health across food-animal species, and includes the topics of immunometabolism, host-pathogen interactions, feed additives and antibiotic alternatives. Dr. Arsenault was previously a post-doctoral research scientist with the United States Department of Agriculture’s Agricultural Research Service (USDA-ARS) where he conducted research on gut health and immunomodulation in chicken and cattle, with the goal of limiting the carry and spread of pathogens important to food safety. Dr. Arsenault received his B.Sc. (2006) and Ph.D. (2012) from the University of Saskatchewan, Canada, in biochemistry and conducted his research at the Vaccine and Infectious Disease Organization - International Vaccine Centre (VIDO-InterVac).
Julie Veryser
Jan Suchodolski
Jan S. Suchodolski graduated with a veterinary degree from the University of Veterinary Medicine in Vienna, Austria in 1997. In 2005 Dr. Suchodolski received his PhD in Veterinary Microbiology from Texas A&M University for his work on molecular markers for the assessment of the intestinal microbiota. He is board certified in immunology by the American College of Veterinary Microbiologists (ACVM). He currently serves as Associate Professor and Associate Director of the GI Lab, a leading research and service laboratory for diagnosis of gastrointestinal disease in companion animals. Over the last 10 years, the GI Laboratory has developed and validated several novel biomarkers for diagnosing and assessing severity of disease in gastrointestinal inflammation and microbiota dysbiosis. His research interest focusses on characterization of intestinal microbiota and metabolome in animal models with spontaneously occurring inflammatory bowel diseases and how the perturbations are modulated by various treatments.